Human medicines European public assessment report (EPAR): Caelyx pegylated liposomal, doxorubicin, Date of authorisation: 20/06/1996, Revision: 39, Status: Authorised

Human medicines European public assessment report (EPAR): Azacitidine Kabi, azacitidine, Date of authorisation: 05/01/2024, Revision: 2, Status: Authorised

Fiasp PumpCart (insulin aspart)

Name Review Group form - questions and answers

NovoRapid PumpCart (insulin aspart)

Human medicines European public assessment report (EPAR): Breyanzi, lisocabtagene maraleucel, Date of authorisation: 04/04/2022, Revision: 11, Status: Authorised

Allergen products development for immunotherapy and allergy diagnosis in moderate to low-sized study populations - Scientific guideline

Human medicines European public assessment report (EPAR): Alyftrek, deutivacaftor / tezacaftor / vanzacaftor, Date of authorisation: 30/06/2025, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Invokana, canagliflozin, Date of authorisation: 15/11/2013, Revision: 27, Status: Authorised

EMA/PE/0000232894